Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global neutropenia treatment market reached a value of about USD 15.69 billion in 2023. The market is projected to grow at a CAGR of 5.3% during the forecast period of 2024-2032 to attain a value of nearly USD 25.09 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In the forecast period, rising awareness of neutropenia and chemotherapy-related side effects, as well as increasing diagnostic technologies, are expected to help accelerate the rise of neutropenia treatment. The significant increase is attributed to a promising therapeutic pipeline that includes around 5 medicines in phase III clinical studies to treat neutropenia. The risk of neutropenia is predicted to increase as the prevalence of leukaemia rises, particularly after treatment.
One of the major drivers of market expansion is new therapies paired with an increase in occurrences of chemotherapy-induced neutropenia. Furthermore, the innovative medication delivery technique improves patient comfort, resulting in increased patient adherence and, as a result, market growth. Furthermore, because cancer is a known cause of neutropenia, the market for neutropenia treatment will benefit from an increase in the number of instances of chemotherapy for cancer treatment.
In the worldwide neutropenia treatment industry, North America held the biggest share. North America has had tremendous expansion in the neutropenia treatment industry, and it is likely to dominate the market in the future years. This is due to an increase in the number of cases of leukaemia in the area. In addition, North America is home to many of the market's main participants. Furthermore, the United States dominates the need for neutropenia therapy in North America. The region's dominance is attributable to an increase in demand for febrile neutropenia medications and the implementation of new legislation to promote and manufacture biosimilars. Throughout the forecast period, the Asia Pacific is predicted to develop at the fastest rate in the market. Due to the increasing number of leukaemia cases and patients undergoing first-line chemotherapy treatment in Asia, the neutropenia treatment industry has a lot of room to grow.
Neutropenia is a rare disease characterised by a sharp drop in neutrophil counts, resulting in weakened immunity. Neutropenia can be caused by a variety of diseases or situations, including chemotherapy for cancer, infections, congenital bone marrow abnormalities, autoimmune disorders, and some medications (drug-induced neutropenia).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of treatment, neutropenia treatment industry is segmented into:
Based on the distribution channel, the market is divided into:
The major regional markets of neutropenia treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The neutropenia treatment industry is expected to increase considerably due to major players in the industry supporting research and development as well as public awareness of neutropenia therapy. Companies in this market are focusing on raising knowledge about preventive measures, early diagnosis, and effective treatment of neutropenia as major market tactics. The introduction of small molecules is one of the major technologies gaining traction in the worldwide neutropenia treatment industry. The development of Plinabulin, a tiny chemical with immune-boosting properties created by BeyondSpring Pharmaceuticals, is expected to transform neutropenia treatment. In addition to its immune-boosting properties, Phase II tests have shown that this chemical has even more effective anti-cancer properties. In the neutropenia treatment industry, there is now a significant need for cost-effective medicines. As a result, suppliers are concentrating their efforts on the development of small molecules that have lower processing costs than biologics.
The report gives a detailed analysis of the following key players in the global neutropenia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2023, the global neutropenia treatment market attained a value of nearly USD 15.69 billion.
The market is projected to grow at a CAGR of 5.3% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 25.09 billion by 2032.
The major drivers of the industry, such as rise in cancer cases leading to development of novel therapies and increasing number of R&D and investments by major players are expected to aid the market growth.
The key market trends guiding the growth of the industry include rising awareness of neutropenia and chemotherapy-related side effects, as well as increasing diagnostic technologies.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America dominating the market share in regional markets.
Colony stimulating factors segment is expected to be the dominant treatment in the industry due to the presence of major players who are focused on the development of colony-stimulating factor based drugs.
The distribution channel segment is led by hospital pharmacies segment of the market.
The major players in the industry are Amgen, INC., Beyondspring, INC., Cellerant Therapeutics, Inc., Kyowa Kirin, Pfizer INC., and Novartis Ag, among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share